Goldman Sachs has reiterated its buy rating on Neuland Laboratories, increasing the target price from ₹13,750 to ₹15,250, indicating a 7% upside from the current market price of ₹14,220. The company posted a weak Q2, as expected, but Goldman Sachs anticipates growth inflection from FY26 onwards.
Goldman Sachs has adjusted its FY25 EPS estimates downward by 13% to account for the Q2 miss. The brokerage also noted a temporary blip in Neuland’s Custom Manufacturing Solutions (CMS) business, though it remains optimistic about long-term growth prospects.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Please consult with a financial advisor before making any investment decisions.